Adult acute lymphoblastic leukemia: concepts and strategies.
about
Novel agents and biomarkers for acute lymphoid leukemiaAdvancements in Therapy for Acute Lymphoblastic Leukemia: BlinatumomabThe role of aberrant proteolysis in lymphomagenesisOccupational benzene exposure and the risk of lymphoma subtypes: a meta-analysis of cohort studies incorporating three study quality dimensionsMurine models of acute leukemia: important tools in current pediatric leukemia research.The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemiaDorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia.Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.Using genetics and genomics strategies to personalize therapy for cancer: focus on melanomaSerum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies.Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramMyc roles in hematopoiesis and leukemiaNew markers for minimal residual disease detection in acute lymphoblastic leukemia.Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia.Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.Mucormycosis during Imatinib treatment: case report.Mixed Phenotype Acute Leukemia with Two Immunophenotypically Distinct B and T Blasts Populations, Double Ph (+) Chromosome and Complex Karyotype: Report of an Unusual Case.Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report and literature reviewRedirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.Effects of Toll-like receptor signals in T-cell neoplasms.B-cell acute lymphoblastic leukemia with t(4;11)(q21;q23) in a young woman: evolution into mixed phenotype acute leukemia with additional chromosomal aberrations in the course of therapyMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaOutcomes of phenylketonuria with relevance to follow-upAre incidence rates of adult leukemia in the United States significantly associated with birth cohort?Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemiaMonitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Remission of lymphoblastic leukaemia in an intravascular fluidic environment by pliable drug carrier with a sliding target ligand.Vascular access devices in leukemia: a retrospective review amongst patients treated at the Ottawa Hospital with induction chemotherapy for acute leukemia.Acute leukaemia: making sense of a complex blood cancer.Leukaemias into the 21st century: part 1: the acute leukaemias.
P2860
Q26829775-5FDB7EFE-BAB5-4263-8914-308055365ACAQ28079934-10D0DB2F-8AE7-4E43-AF93-97FD413D3E79Q28084404-2DFAB5A7-FDCD-44B3-8D58-6C3A0314CBC5Q28386274-845B0F63-47EA-4FB8-BF2F-CBE52A59B4F7Q33606018-5AA03F10-C0EE-4383-9099-21DBBA99D1EBQ33737761-00DC2CC1-8D8C-4B9B-A588-E163C9517C3AQ33790257-CB2A9B1C-196F-454C-B0DB-D7E2A7701D83Q33893777-3C262F21-941C-4688-9952-880BE6DE81BCQ33915990-93FEACF4-B189-434D-BA14-4804CF66F93BQ33965328-BEB26D1A-1A12-43A1-B822-18C2958C3DBBQ34333169-11386A90-AE82-4112-BB7B-589CA7F304E7Q34401741-91016370-B3D3-4BFD-A77A-2B8E4613E719Q34543909-831BBEC9-11C8-416F-A06A-21356E2192F9Q34972364-2F4C3389-3D61-4C3D-9988-61CAA8820AF1Q35067391-C55D52F7-1118-4D9D-BD2B-96F1FCF7D04FQ35178420-EB135B03-6E77-4374-9F9F-3BE330A9239AQ35182716-3CF65116-813E-4228-9618-2B804DE8A0F9Q35183900-15531A0A-9FED-4B67-9B0B-5F3186214C7CQ35659879-E0CB173E-DC01-4991-A079-464D8758559CQ35801603-1DAF4629-A2E8-4736-BC79-81821F9DC6F0Q35820095-CCB93879-BBF4-41E3-81C1-ABA38DE4DC5AQ36017718-25333233-8850-4EB6-9522-BA471F202AF9Q36082395-CDD25877-2742-4C03-BBE5-0C31C2DA5537Q36085424-9480688F-1889-4EE0-A9B4-B6904525BF0BQ36131489-FCDDCCF9-48D3-4A5E-8228-ABB2DCC7B642Q36216252-49AA4086-A0F2-4A0F-861D-9FFDD34B747BQ36293678-1080A15E-A7C2-41DF-B875-0EE1E778E105Q36331741-2B755C70-98B4-4243-911C-A92B1FB3BA90Q36339717-0D810564-9E01-47DE-82EB-082A943407C2Q36433235-3F681685-BA88-44C6-BE01-56F05B607771Q36457229-F0400C83-F610-46E1-AB68-3D2DE88429D8Q36544778-B53DE79A-98E5-4E2E-AA61-F45EE7AFE208Q36561755-B5C59B14-1137-481D-B52B-6734B4E1F415Q36616666-4BF54085-21BB-4C29-BAB0-8560749D328BQ37039074-D24759DE-1177-4001-AFBA-7CBFC0DC65CEQ37370563-275E7319-B8EE-44C2-9FC5-C0C07DD98F5AQ37588983-9E8C9D1B-BD08-4982-87FC-B0BD4552FF04Q37955710-B9FAFCC9-54ED-4E51-A2F5-E6FE51ACE6AFQ37981504-5DAA92DB-B1F3-42C3-88E4-C8086213799DQ38060223-BE990CA4-E3C0-4DA8-89EA-15D3514EBF26
P2860
Adult acute lymphoblastic leukemia: concepts and strategies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adult acute lymphoblastic leukemia: concepts and strategies.
@en
Adult acute lymphoblastic leukemia: concepts and strategies.
@nl
type
label
Adult acute lymphoblastic leukemia: concepts and strategies.
@en
Adult acute lymphoblastic leukemia: concepts and strategies.
@nl
prefLabel
Adult acute lymphoblastic leukemia: concepts and strategies.
@en
Adult acute lymphoblastic leukemia: concepts and strategies.
@nl
P2093
P2860
P50
P356
P1433
P1476
Adult acute lymphoblastic leukemia: concepts and strategies.
@en
P2093
Dieter Hoelzer
Meir Wetzler
Wendy Stock
P2860
P304
P356
10.1002/CNCR.24862
P407
P577
2010-03-01T00:00:00Z